Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

New research on drug yields promising results

By Zhang Yangfei | China Daily | Updated: 2020-03-18 08:19
Share
Share - WeChat
A lab assistant tests drugs at a pharmaceutical company in Harbin, capital of Heilongjiang province, on March 4, 2020. [Photo/Xinhua]

Chinese researchers have completed clinical studies of favipiravir, which shows promising clinical efficacy in treating the novel coronavirus pneumonia, Zhang Xinmin, head of the China National Center for Biotechnology Development, said on Tuesday.

Experiments have shown that patients treated with favipiravir recovered more quickly and their lung conditions improved better than patients in the control group, he said.

Some pharmaceutical enterprises have already obtained drug approval from the State Food and Drug Administration for mass production in February, so the supply of favipiravir is guaranteed, he said, adding that researchers have already recommended the drug be included in the treatment plan as soon as possible.

The Third People's Hospital of Shenzhen in Guangdong province conducted a clinical trial on 80 patients, with 35 receiving the drug. The results showed that patients who took favipiravir tested negative within four days of treatment, whereas patients in the control group needed 11 days to test negative.

The lung conditions of 91.4 percent of the treated group improved as shown in chest imaging, compared with 62.2 percent of the control group, Zhang said.

In another experiment on 120 patients conducted by Zhongnan Hospital of Wuhan University in Hubei province, the treated group had a higher recovery rate at the end of the treatment; further, fever reduction and cough relief took less time for them, he added.

In terms of safety, Zhang said, the drug-developed in Japan and approved for marketing there in 2014-has shown no obvious adverse effects.

"In view of the safety, obvious efficacy and availability of the drug, researchers have officially recommended favipiravir to medical teams and suggested it be included in the treatment plan as soon as possible," he said.

Zhang said the research team will further promote the application of their research results in Wuhan and will promote the Chinese treatment plan in response to the current global pandemic situation.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 国产尤物二区三区在线观看| 中文字幕日韩精品无码内射| xxxxx做受大片视频免费| 污视频免费看网站| 天天色天天操天天| 亚洲伊人久久大香线蕉| 色吊丝中文字幕| 国内精品久久久人妻中文字幕| 五月丁六月停停| 精品无人区麻豆乱码1区2区| 国产系列在线播放| 久久99精品久久久久麻豆| 波多野吉衣一区二区三区在线观看| 啊灬啊灬啊灬快灬高潮少妇| 1000部免费啪啪十八未年禁止观看| 无人视频在线观看免费播放影院| 亚洲精品人成无码中文毛片| 鲁啊鲁在线视频| 国语精品91自产拍在线观看二区| 久久久无码精品亚洲日韩按摩| 狠狠精品干练久久久无码中文字幕| 国产女人乱人伦精品一区二区| a级情欲片在线观看hd| 日本高清乱理论片| 亚洲精品天堂成人片AV在线播放| 被公侵犯肉体的中文字幕| 国产麻豆精品原创| 久久久久成人精品| 欧美色图亚洲自拍| 午夜视频久久久久一区| 人人影院免费大片| 天堂а√在线地址| 久久久久久久极品内射 | 女人张开腿让男桶喷水高潮 | 野外三级国产在线观看| 国产精品综合一区二区三区| 东北壮汉gayxxxvideo| 欧美a级毛欧美1级a大片免费播放| 劲爆欧美第1页婷婷| 黄色免费在线观看网址| 在线观看成人网站|